Speaker

  • Heiko Bruhn
    Heiko Bruhn GenSearch
    Heiko Bruhn

    Talent Panel: Digitalization in Human Resources

    Technology has revolutionised the way we access information, and thereby the way we do business. Regardless of industry, every company and every industry can now be digital and has the potential to be global. An abundance of information makes it possible for companies to segment and personalise products and services. lt also enables companies to quickly move into other new spaces of innovation.

    These changes will have a deep impact on the workplace. The way workforces are structured and organised will have to change fundamentally, leading to many knock-on effects in human capital management. Thus organisations will need to rethink the way they hire, engage, develop, reward and lead their workforces. Two points to discuss:

    Targeted recruitment driven by social media and cognitive assessment

    Recruitment can be honed and focused through digital tools such as social media and cognitive assessment.

    Transformation of leadership: In this new world it will be less about leading people and more about orchestrating the ecosystem of work.

    Curriculum Vitae

    Heiko Bruhn 
    Managing Director Switzerland-Germany-Austria, GenSearch

    Heiko is an Attorney at Law. He graduated from the University of Freiburg/Breisgau with specialization in Labour and Social Security Law. Heiko joined Roche as a Human Resources Manager in 1992. During his time at Roche he take on a wide range of roles within the international human resources department. His many years of experience supporting international fields such as commercial, clinical development, medical affairs means he has strong contacts within the pharmaceutical and biotech sectors. Since 2010 he is acting as Executive Search Consultant and Coach.
    He joined GenSearch in 2017, establishing the Swiss branch. He advised life science companies on the appointment of senior executives in Switzerland, France, Benelux, Germany and Nordics.

    In addition, since 2012, Heiko has given lectures at the DHBW University in Lörrach for employer branding and recruitment.

  • Giuseppe Conti
    Giuseppe Conti Conti Advanced Business Learning
    Giuseppe Conti

    Creativity in negotiation

    It's probably no coincidence that the Spanish word for business is "negocios". It highlights the importance of the negotiation when doing business. Although in M&A we pride ourselves with being strong negotiators, there is always room to get better. Since negotiation is practical skills, we will learn together by doing a role play and then getting a debrief and a video debrief on our performance from a leading negotiation expert.

    The role play is aimed at pulling us out of our comfort zone since it describes the negotiation between the developer of a new shopping center and a major retail chain. The negotiation is on an impasse and you will need to use your creative negotiation skills to reach an agreement. An opportunity to use our skills in a different context.

    Curriculum Vitae

    Giuseppe Conti
    Founder, CABL

    Prof. Giuseppe Conti is the founder of CABL (www.cabl.ch), a firm that offers a range of customized training in the field of negotiation and influencing.

    Since 2005, he is an award-winning Professor and Lecturer at leading business schools throughout Europe (Cambridge, ESADE, HEC Lausanne, HEC Paris, IESE, IMD, Imperial College, INSEAD, London Business School, Oxford, RSM, SDA Bocconi, UBIS, University of Geneva, and University of St. Gallen), recognized for his lively and interactive training workshops. 

    He runs negotiation workshops in four continents. Giuseppe is an accomplished negotiator and integrates into his training over 25 years of executive-level experience, mainly in Procurement, at Blue Chip corporations (Procter & Gamble, Novartis, Merck). You can reach him on giuseppe.conti@cabl.ch

    His recent research and articles have focused on negotiating with no alternatives, influencing in healthcare, gender differences in negotiation, managing internal and external negotiations, dealing with difficult people, and cross-cultural negotiations.

  • Matthias Fehr
    Matthias Fehr HBM Partners AG
    Matthias Fehr

    Challenges of transforming a game-changing business idea into a company and of funding high-risk biopharma ventures

    Bringing innovative products to market requires expertise, financial resources, and perseverance. The founder of Vicarius Pharma will share insights gathered while transforming a new in-licensing business model for US innovator products wishing to commercialize in Europe into a business platform. He will also talk about how finding investors requires focus and a clear positioning even in times when large amounts of capital are looking for investment opportunities.

    Finding the “next big thing in biotech” can be a powerful driver for venture capitalists. However, commercial, clinical and regulatory risks are increasingly hard to estimate. In addition, with the growing concerns by payors regarding the cost of drugs, reimbursement risks are difficult to assess. In his presentation, Matthias Fehr will share some recent examples of how HBM managed to successfully fund promising ventures.

    Curriculum Vitae

    Matthias Fehr
    Head Private Equity, HBM Partners AG

    Dr. Matthias Fehr, Member of the Management of HBM Partners AG, Head Private Equity and Investment Advisor to HBM Healthcare Investments AG. He has over twenty years of experience in private and public equity investment management and research. He was senior sell-side analyst at Lombard Odier for biotech and medical technology industries and worked as a scientist at the Swiss Federal Institute of Technology. MSc and PhD in chemistry from ETH Zurich and Chartered Financial Analyst since 2002. Board member of Swixx Biopharma, Sphingotec and Farmalatam and board observer at Sai Life Sciences and 1mg.

  • Shayesteh Fürst-Ladani
    Shayesteh Fürst-Ladani SFL Group of Companies
    Shayesteh Fürst-Ladani

    Regulating tomorrow’s healthcare technologies: promoting innovation and patient access while maintaining consumer safety and privacy

    Disruptive healthcare technologies are redefining patient healthcare, with early successes including curative genetic treatment in regenerative and anti-cancer therapy, to marked improvements in quality of life through precision medicines and devices for complex and chronic diseases.

    The rapid rise of these disruptive technologies has also exposed gaps in existing regulations and inadequate provisions to assure patient safety and privacy.

    Over the last ten years the EU has updated regulatory frameworks for products utilizing cells and genes, medicinal products, medical devices, and consumer privacy and data protections. The EU has also implemented regulatory support processes and financial incentives to promote innovation and continued development.

    Successful integration of new digital, genetic and manufacturing technologies, including utilization of artificial intelligence, mobile health applications, connected biosensors and genetic editing in medical products, requires a clear understanding of these frameworks and benefits.

    Curriculum Vitae

    Shayesteh Fürst-Ladani
    CEO, SFL Group of Companies

    Shayesteh Fürst-Ladani is the CEO and founder of SFL Group of Companies.

    She has extensive experience in negotiating companies’ interests at a senior level in meetings with regulators. Shayesteh has been involved in reviewing and assessing the impact of European and US legislation, such as the Cell & Tissue Directive, the Advanced Therapy Medicinal Products Regulation, the Orphan Medicinal Product Regulation, Drug & Device Combination Products and Personalized Medicine.

    Shayesteh is President of the  “Rare Disease Action Forum” (RDAF) as well as the “Medtech & Pharma Platform” (MPP) Associations. She is frequently invited as speaker and/or conference chair. Shayesteh is >Special Coach at Innosuisse, Adjunct Instructor for Regulatory Affairs at the George Washington University as well as Lecturer at IFPMA/Kings College.

    Before founding SFL, Shayesteh hold senior positions in various biotech and major pharmaceutical companies as Head of Global Regulatory Affairs and Head of Regulatory Affairs for Development Products.

  • Frank Grams
    Frank Grams Everest Medicines
    Frank Grams

    Alliance Management: Deal keeping in the rough - How to keep your alliance alive? 

    When Pharma started seriously doing Alliance Management about 20 years ago it was an unknown profession. Selling it to your own management and the Business Development organization has been a hard task. Often it has been seen as a pure relationship management activity and as an activity that can be easily cut when financial stress hit the companies. Today it is widely recognized as a key function to improving the likelihood of generating value out of a business relationship.

    Over the years the profession converged from diverse islets with different definitions to a solid function that today is used across the portfolio and across the industries always with the focus on generating value out a deal that has been signed without the ability of looking into the future.

    Most alliances go through rough water at some point at time. It is important to keeping the overview, aligning everyone on board and ensuring to reach the targeted destination of the journey or finding a better alternative. For companies with a portfolio of alliances this better alternative could also be to sacrifice an alliance for the sake of the others.

    Curriculum Vitae

    Frank Grams
    SVP Alliance Management and SVP Business Development Europe, Everest Medicines

    Frank is the SVP Global Head of Alliance Management and European Head Business Development at Everest Medicines and currently based in Paris, France. He used to be the VP, Head of R&D Alliance Management and later VP, Alliance Management, General Medicines, Emerging Markets and Consumer Health Care at Sanofi. During this time he has also been the Risk Management leader of the Strategy & Business Development group and a permanent member of the Sanofi Corporate Risk Committee. He also served as an Advisory Board member of ASAP.

    Prior to Sanofi he was serving Roche in a number of Business Development roles. As Executive Director, Pharma Partnering, he helped to build Business Development in Asia Pacific based out of Shanghai. Before moving to China, he led the Lifecycle Management Partnering group in Basel.

    Before switching to Business Development, he served in various Research positions for Roche in Switzerland and for Boehringer Mannheim in Germany. He holds a PhD in Chemistry from TU Munich (MPI Biochemistry, Martinsried, lab of Nobel laureate Robert Huber) and a Non-Executive Director Diploma of Financial Times/Pearson.

  • Peter Grünenfelder
    Peter Grünenfelder Avenir Suisse
    Peter Grünenfelder

    Global trends in the healthcare sector and policy implications

    Across the OECD, healthcare costs are on the rise, while healthcare systems face new challenges. A changing demographic landscape with aging populations and increasing longevity puts pressure on health care resources. Ageing-related diseases are becoming more prevalent, as are chronic and mental illnesses. Developing patient expectations lead to new demands that require more complex solutions. At the same time, technological innovations are gradually transforming the healthcare sector, which brings both opportunities and challenges. What do these developments mean for the healthcare sector especially in Switzerland? Does the current political environment allow for the necessary responses? Peter Grünenfelder explores these questions and suggests liberal and market-oriented ideas for a healthier tomorrow.

    Curriculum Vitae

    Peter Grünenfelder
    Director, Avenir Suisse

    Peter Grünenfelder is Director of Avenir Suisse, the leading Swiss think tank. He holds a Ph.D. in business administration from the University of St. Gallen. Peter is a frequent visiting lecturer at universities in Switzerland and abroad.

  • Hans Peter Hasler
    Hans Peter Hasler Vicarius Pharma
    Hans Peter Hasler

    Challenges of transforming a game-changing business idea into a company of funding high-risk biopharma ventures

    Bringing innovative products to market requires expertise, financial resources, and perseverance. The founder of Vicarius Pharma will share insights gathered while transforming a new in-licensing business model for US innovator products wishing to commercialize in Europe into a business platform. He will also talk about how finding investors requires focus and a clear positioning even in times when large amounts of capital are looking for investment opportunities.

    Finding the “next big thing in biotech” can be a powerful driver for venture capitalists. However, commercial, clinical and regulatory risks are increasingly hard to estimate. In addition, with the growing concerns by payors regarding the cost of drugs, reimbursement risks are difficult to assess. In his presentation, Matthias Fehr will share some recent examples of how HBM managed to successfully fund promising ventures.

    Curriculum Vitae

    Hans Peter Hasler 
    Founder and CEO, Vicarius Pharma

    Hans Peter Hasler is a senior executive and top-level advisor to the life-sciences industry. He has an international track record and in-depth operational, commercial, and general management expertise. Mr. Hasler has managed the growth of leading players in the pharmaceutical industry and has successfully launched several blockbuster drugs.

    Mr. Hasler has built an extensive network with leading pharmaceutical and biotechnology corporations. He is Chairman of the Board of HBM Healthcare Investments AG in Zug; Director of the Board of Minerva Neuroscience Inc., Boston; Member of the Board of Shield Therapeutics PLC, London; and Chief Advisor of SBTech Advisory, a small asset scouting company located in Israel, Switzerland, and the USA.

    Hans Peter Hasler is founder and CEO of Vicarius Pharma. The company develops and executes European go-to-market strategies for specialty, rare/orphan, and hospital products.

  • Ingmar Hoerr
    Ingmar Hoerr CureVac AG
    Ingmar Hoerr

    Keynote Speech

    The greatest healthcare disruption is on its way! Patient specific treatments not just for therapy but also for the maintenance of health.

    Artificial intelligence generates more and more data in silico on the emergence and root cause of diseases and malfunctions of the body. These data need to be confirmed by assays in “wet labs” and robust disease modelling in animals and non-animal test-systems. Huge sets of protein data can be applied in vivo by encoding them on genetic sequences on mRNA. Cells and tissues are capable of taking up mRNA and efficiently express proteins in situ. 

    This methodology might give access to new datasets for complex pathways responsible for causing diseases like Cancer, Alzheimer and Parkinson’s.

    Confirmed protein datasets resulting in potential therapeutic proteins can be encoded on therapeutic mRNA and these mRNA sequences can be printed out in a GMP miniature RNA synthesizer within days. CureVac has already invented a prototype enabling rapid mRNA production in gram scale encoding a huge variety of proteins which can be applied directly to human tissue to treat or prevent complex diseases. If this technology receives approval in the future, medical doctors could start to directly print personalized drugs at their premises. If this comes into reality the whole conventional pharma value chain will be affected by these disruptive changes for the benefit of human beings.

    Curriculum Vitae

    Ingmar Hoerr
    Chairman of the Supervisory Board, CureVac AG

    Ingmar Hoerr, PhD, MBA, Chairman of the Supervisory Board founded the biopharmaceutical company together with colleagues in the year 2000 in Tuebingen. His entrepreneurship was motivated by a surprising discovery during his doctoral research. Experiments conducted for his research showed that the mRNA molecule class can be injected into tissue directly and is capable of expressing genetic information into proteins effectively as well as generating a strong specific immune response, contrary to what had previously been believed. From this key discovery, in his role as CEO he built up a company that was the first ever to treat a human subject with an mRNA drug and that is now a leading German “unicorn” in the research and development of mRNA-based drugs. Since its inception, CureVac has received approximately €400 million in equity investments. CureVac has created 400 jobs in Tübingen, Frankfurt and Boston and collaborates with world leading pharma companies.

    Ingmar Hoerr received his PhD in Immunology from the University of Tübingen and his MBA from Danube University, Krems, Austria. Furthermore, he is member of the Board of the European Innovation Council at the European Commission and he is juror of the German founder prize award “Weconomy”. He served on the Founding Board of the Agency of Disruptive Innovations “SprinD“ initiated by the German government. He is honorary senator of the University of Tuebingen and he is a member of the Board of Trustees of the Max Planck Society.

  • Michael Huebner
    Michael Huebner Johnson & Johnson Innovation
    Michael Huebner

    Diamonds in the rough - Accelerating External Innovation

    Research and development costs associated with developing novel transformative therapeutics are increasing while sales in some areas are expected to decline, at least in part due to the market entry of generics and biosimilars. At the same time, mounting competition for accessing external innovation leads to increasing deal values across the board: The innovation model in the pharmaceutical industry is under pressure from several directions.

    Some companies are seeking to fill their pipelines and maintain their market share by accessing de-risked late stage assets which promise near-term sales – and they are willing to accept the high price tag. Others are looking for earlier stage innovation and they accept the high risk of failure associated with it.

    In this presentation I will highlight the various strategies which pharmaceutical companies are pursuing for accessing early-stage external innovation, and I will discuss the opportunities and risks associated with these approaches.

    Curriculum Vitae

    Michael Huebner
    New Venture Lead, Johnson & Johnson Innovation

    Michael Huebner is New Venture Lead at Johnson & Johnson Innovation, where he is responsible for establishing partnerships with life science companies and academic centers. His focus is on Switzerland across all Johnson & Johnson healthcare business areas, as well as on therapeutics for oncology in the EMEA region. Michael is a member of the Johnson & Johnson Switzerland leadership team, Janssen EMEA Strategic Alliances Network and Actelion/J&J campus management committee.

    Prior to joining Johnson & Johnson, Michael was Business Development and Licensing Manager at Roche where he led licensing and acquisition deals totaling over 1bn CHF.

    Before joining Roche, Michael was a scientist at Cold Spring Harbor Laboratory (USA), where he worked as an EMBO fellow and DAAD scholar and he earned a PhD summa cum laude from EMBL.

  • Emily Leproust
    Emily Leproust Twist Bioscience
    Emily Leproust

    The Plan is the Plan Until the Plan Changes: Navigating the Challenges of Scaling DNA Synthesis

    Twist Bioscience was founded in 2013 by three co-founders: Emily Leproust, Bill Banyai and Bill Peck. Twist makes DNA from scratch to enable customers to improve health and sustainability. Synthetic DNA can be used to develop diagnostic tests and protein therapeutics, remove harmful petrochemicals from the production of chemicals and biomaterials including fragrances, flavors and even silk, improve agricultural yields to ensure food security and even store digital data in DNA.
    Come hear how the team has successfully commercialized disruptive technology, navigated obstacles, overcame founder myths widely believed to be true. The journey to get to $54.4 million in revenue for fiscal 2019 has been challenging, with twists and turns at each step. This is the story of Twist, with practical advice for founders, executives and investors alike to meet milestones and build a robust business.

    Curriculum Vitae

    Emily Leproust, Ph.D. 
    CEO, Twist Bioscience

    As an early pioneer in the high-throughput synthesis and sequencing of DNA, Dr. Leproust is disrupting the process of gene synthesis to enable the exponential growth of synthetic biology applications in multiple fields including medicine, DNA data storage, agricultural biology, and industrial chemicals. In 2015, she was named one of Foreign Policy’s 100 Leading Global Thinkers for fast-tracking the building blocks of life, and Fast Company named her one of the most creative people in business for synthesizing DNA faster than ever.

    Prior to Twist Bioscience, she held escalating positions at Agilent Technologies where she architected the successful SureSelect product line that lowered the cost of sequencing and elucidated mechanisms responsible for dozens of Mendelian diseases. She also developed the Oligo Library Synthesis technology, where she initiated and led product and business development activities for the team. Dr. Leproust designed and developed multiple commercial synthesis platforms to streamline microarray manufacturing and fabrication. Prior to Agilent, she worked with Dr. X. Gao at the University of Houston developing DNA and RNA parallel synthesis processes on solid support, a project developed commercially by Xeotron Corporation.

    Dr. Leproust has published over 30 peer-reviewed papers—many on applications of synthetic DNA, and is the author of numerous patents. She earned her Ph.D. in organic chemistry from the University of Houston and her M.Sc. in industrial chemistry from the Lyon School of Industrial Chemistry in France.

  • Sabin Llona-Mínguez
    Sabin Llona-Mínguez LabGenius Ltd
    Sabin Llona-Mínguez

    The AI-driven drug discovery revolution: adoption through deal-making

    Artificial intelligence (AI) technologies are starting to play a central role in pharmaceutical research, with applications ranging from biomedical data mining, to chemical synthesis, to clinical trial optimization. As activity moves beyond the early technology adopters, venture capital keeps pouring into AI-driven drug discovery startups, larger pharmaceutical organizations increase their commitments through partnerships and reorganizing their business around AI technologies too.

    The pharmaceutical industry's quest to 1) defeat Eroom's law (drug discovery is becoming slower and more expensive over time, despite improvements in technology) and 2) tackle tougher medical challenges now that the low hanging fruit has been harvested, are at the core of the AI revolution.

    This presentation will provide an overview of the research approaches in AI-driven drug discovery, the companies spearheading their implementation, and their impact on pharmaceutical deal-making.

    Curriculum Vitae

    Sabin Llona-Mínguez
    Business Development and Innovation Manager, LabGenius Ltd

    Sabin is leading search and evaluation, business development and licensing activities activities at LabGenius, the first biotechnology company using machine learning-directed evolution to develop next generation antibody therapeutics.

    Sabin has 10+ years experience working in the pharmaceuticals' business, holding business development and research positions at Cancer Research Technology, GlaxoSmithKline and the Karolinska Institute. He was educated as a pharmacist at the University of Barcelona and received his PhD degree in Medicinal Chemistry from the University of Strathclyde.

  • Thomas Meier
    Thomas Meier Santhera Pharmaceuticals
    Thomas Meier

    Case Study: Lessons learned from Biotech

    Early stage biotech companies face ever demanding challenges and rapidly need to adapt to new situations. I will share experiences and lessons learned from my 20 years as scientist, entrepreneur and executive manager in an emerging pharmaceutical company.

    In 2019, Santhera was celebrating its 15th anniversary! Over the years, between being declared dead or celebrated as everybody's darling, we stood firm behind our vision and developed Santhera into a company with a promising product pipeline nearing market roll-out. On our path, we executed bold moves, took courageous and tough decisions, consciously balancing risks against desired returns. Looking back, today’s success by far outweighs past challenges. Certainly a key lesson we learned was the importance of commitment and perseverance to be successful.

    Santhera is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare diseases with high unmet medical need. The portfolio comprises clinical stage treatments for neuromuscular and pulmonary diseases and a marketed product for a neuro-ophthalmologic disease.

    Curriculum Vitae

    Thomas Meier
    Founder, Board of Directors, Santhera Pharmaceuticals 

    Thomas Meier holds a PhD in Biology from the University of Basel and carried out post-doctoral training at the University of Colorado Health Sciences Center (USA) and Biozentrum, University of Basel, where he became group leader and lecturer in Neurosciences before joining the industry. He has a distinguished scientific track record in the field of neuromuscular research.

    As entrepreneur, he established MyoContract in 2000, a research company focused on orphan neuromuscular diseases and the first start-up company originating from the Biozentrum. In 2004, he co-founded Santhera and served on Santhera’s Executive Management as Chief Scientific Officer (CSO) and from 2011 as CEO. In 2017, he became Member and Delegate of the Company’s Board of Directors.

    As CSO he actively contributed to Santhera’s IPO on the SIX Swiss Exchange in 2006, and as CEO has restructured the company, extended the clinical stage product development pipeline by creative licensing deals, expanded Santhera’s footprint to several European countries and the US and successfully launched an innovative orphan disease product in Europe which he then sold after four years of steady sales growth.

    In 2007, he received the BioValley Basel Award for his outstanding contributions to the life sciences in the area.

  • Walter Oberhänsli
    Walter Oberhänsli Zur Rose Group
    Walter Oberhänsli

    Disruption in the pharmacy market

    In other sectors, digital technologies and e-commerce are already firmly established, but digitalisation in healthcare is still lagging behind expectations. The Zur Rose Group successfully backed digital processes at an early stage: they create transparency and avoid errors as a result of media discontinuities.

    Zur Rose is keen to expand the digital service portfolio by linking and providing data and creating a wide-ranging health ecosystem so as to make further contributions to increasing therapy adherence, improving healthcare provision and reducing the cost burden on the healthcare system and patients. Zur Rose is also at the cutting edge when it comes to the national launch of electronic prescriptions in Germany in 2020: technology we developed is being used in a pilot project by the largest German health insurer.

    We strongly believe that digital networking will create major added-value for all.

    Curriculum Vitae

    Walter Oberhänsli
    CEO, Zur Rose Group

    Walter Oberhänsli (1958) has served as Executive Director and CEO of the listed Zur Rose Group since 2005. From 1996 to 2011, he was also Chairman of the Board. He established the business, which now employs approx. 1,500 people, in 1993 together with 21 medical doctors.

    Until 2004, he practiced as an independent lawyer. Walter Oberhänsli studied law at the University of Zurich.

  • Clemens Schmid
    Clemens Schmid Roche Diagnostics International Ltd
    Clemens Schmid

    Curriculum Vitae

    Clemens Schmid
    Head of HR, Roche Diagnostics International Ltd

    Clemens Schmid has a Master of Economy (main studies in Leadership & Human Resources, Social Security and Health Economics) from the University of Basel as well as an Executive Master of Human Resources FIBBA from the Academy for Technics, Economics and Social Relationships, Northwestern Switzerland. In his current role as Head of HR, Roche Diagnostics International in Rotkreuz/Zug, he is responsible for the HR Strategy and HR Partnering at Roche’s main Diagnostics site in Switzerland.

    Clemens has over 18 years of HR experience across all divisions of F. Hoffmann-La Roche Ltd and worked in global, regional and local HR leadership roles in Switzerland, the UK, the US, Germany and Brazil before returning to his home country Switzerland in 2019. In addition to his deep HR experience, Clemens has a passion for people and organizational development and an excellent learning agility.

  • Marc Sluijs
    Marc Sluijs DigitalHealth.Network
    Marc Sluijs

    Digital Health & Digital Therapeutics - evolution of the market landscape

    Digital health and digital therapeutics already start having an impact on patients, healthcare providers, payers and the life sciences industry, as also illustrated by a growing body of clinical and economic evidence, and by the almost $20Bn in venture capital invested in digital health in 2018 (roughly the equivalent of all venture investment in medical devices and biotech combined).

    The last 5 years have seen a strong growth in investment in digital health by the pharma industry, with the majority of the top 30 companies investing in digital health companies, establishing a wide range of partnerships, and creating in house digital health capabilities.

    In this overview I’ll provide a snapshot of some of the major developments:

    • Investment trends, M&A, partnerships
    • Strategic industry involvement in digital health: Pharma and Medical Device companies, but also Insurance companies
    • Early examples of Life Sciences deals with digital therapeutics companies

    Curriculum Vitae

    Marc Sluijs
    Founder, DigitalHealth.Network

    Marc’s passionate about fostering the digital health ecosystem, with a particular focus om scaling the digital health sector as facilitator of M&A, growth investment, and life-sciences industry partnerships.

    Marc is currently advising large venture and private equity investors, life sciences and insurance companies with regards to M&A and investment in digital health, and helping digital health companies achieve scale and exits. As advisor to several digital therapeutics companies, Marc is also involved in licensing collaborations with pharma companies.

    Marc has 20+ years of experience working with the Life Sciences industry, information enabled business models (IMS Health/IQVIA), Life Sciences management consulting (Accenture), and biotech (MerckSerono). Most recently, Marc was responsible for M&A and digital health partnerships at Oracle Health Sciences, where his involvement ranged from projects such as the acquisition of ClearTrial and the partnership with Greenphire to Oracle's investment in Proteus Digital Health.

    Marc is a Swiss/Dutch national living in Switzerland; he studied Business Administration at Erasmus Rotterdam (Netherlands) as well as in Aix-en-Provence (France); he speaks English, French, Dutch and German.

  • Joerg Tritschler
    Joerg Tritschler Simon Kucher & Partners
    Joerg Tritschler

    Pricing of breakthrough therapies - How will healthcare systems handle cure

    The recent surge of breakthrough cell & gene therapies in the ultra orphan space has led to new challenges for payers and healthcare systems alike. As these therapies are often associated with one-time injections, limited trial evidence, high upfront costs and uncertain patient numbers, new P&MA solutions are required by the industry.

    In today’s session we will shed light on:

    • What can be learned from recent reimbursement decisions?
    • How are healthcare systems beginning to change?
    • What are the key steps to success for launching your breakthrough therapy?

    Curriculum Vitae

    Joerg Tritschler
    Senior Director, Simon Kucher & Partner

    Joerg Tritschler is a Senior Director in the Life Science Division of Simon-Kucher & Partners in Zurich, Switzerland. Before, he worked at the headquarters in Bonn and Munich for seven years and the San Francisco office for half a year. He joined Simon-Kucher & Partners in 2011, and has worked in the Life Science division since that time.

    Joerg earned two Master degrees, a M.A. in International Management and a M.A. in Finance, both at the University of St. Gallen. He wrote his Master thesis for Sandoz regarding the valuation of risks and chances arising for Sandoz upon the introduction of the AMNOG act in Germany.

    Since joining Simon-Kucher, Joerg has specialized in international pricing & market access of pharmaceuticals and commercial excellence with a focus on:

    • International P&MA, go-to-market, and innovative pricing strategies
    • Price management, contracting and commercial strategies
    • Clinical trial optimization and portfolio development strategies
    • In addition, he is an expert on payer negotiation training and prepares clients for negotiations with authorities

    Joerg has worked on and led many multinational projects for major several life science clients, mid-size companies as well as international startups across a wide variety of therapeutic areas and indications including oncology, (ultra) orphan disease, cell & gene therapies and chronic diseases.

  • Guillaume Vignon
    Guillaume Vignon BeiGene
    Guillaume Vignon

    Curriculum Vitae

    Guillaume Vignon
    Senior Vice President Business Development, BeiGene

    Guillaume Vignon is Senior Vice President Business Development at BeiGene, responsible for leading all business development activities, from search & evaluation of partnering opportunities across several therapeutic areas, and all the way through till deal closing.   

    Previously, Guillaume was Vice President, Global Head Oncology and Immuno-Oncology Licensing & Business Development at Merck KGaA / EMD Serono. Throughout his career, Guillaume led the closing of complex transactions and forged several strategic partnerships in the fields of Immuno-Oncology, Oncology, Companion Diagnostic, and Antibody Discovery.

    Guillaume holds a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6 / Institut Pasteur, and an MBA from Hult International Business School, Cambridge, MA.